论文部分内容阅读
目的 :探讨乳腺富脂质癌的临床病理特征、诊疗及预后。方法 :回顾性分析2002年5月—2008年11月确诊的7例乳腺富脂质癌患者的临床病历资料及随访资料,Kaplan-Meier法计算生存率并绘制生存曲线。结果 :7例乳腺富脂质癌患者中,男性1例,女性6例;确诊时的中位年龄为48岁(范围:42~91岁);临床分期:Ⅰ期1例,Ⅱ期5例,Ⅲ期1例;雌激素受体、孕激素受体、人表皮生长因子受体2阳性表达均为3例(42.9%);病理分型:luminal A型1例,luminal B型3例,三阴型3例。7例患者的中位生存时间为37个月(范围:8~90个月);中位无病生存时间为27个月(范围:6~90个月)。2年总生存率为57.1%,5年总生存率为28.6%。临床分期是预后的影响因素(χ2=8.692,P=0.013)。结论 :本研究报道了迄今为止国内第2例男性乳腺富脂质癌患者。7例的病理分型未见HER-2过表达型。临床分期是乳腺富脂质癌患者的预后影响因素。
Objective: To investigate the clinicopathological features, diagnosis and prognosis of breast-rich lipid-rich cancer. Methods: The clinical data and follow-up data of 7 breast cancer patients with lipid-rich carcinoma diagnosed from May 2002 to November 2008 were retrospectively analyzed. The survival rate was calculated by Kaplan-Meier method and the survival curve was drawn. Results: Among the 7 patients with lipid-rich breast cancer, there were 1 males and 6 females. The median age at diagnosis was 48 years old (range: 42-91 years). The clinical stage was stage Ⅰ in 1 case and stage Ⅱ in 5 cases , 1 case in stage Ⅲ, 3 cases (42.9%) were positive for estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2. The pathological types were luminal A type in 1 case, luminal B type in 3 cases, Three negative in 3 cases. Seven patients had a median survival of 37 months (range, 8 to 90 months) and a median disease-free survival of 27 months (range, 6 to 90 months). 2-year overall survival was 57.1%, 5-year overall survival rate was 28.6%. Clinical stage is the prognostic factor (χ2 = 8.692, P = 0.013). CONCLUSIONS: This study reports the second case of breast cancer in China with lipid-rich cancer to date. No pathological type of HER-2 overexpression was found in 7 cases. Clinical staging is a prognostic factor in breast-rich lipid-rich cancer patients.